Sugi Predict

Sugi Predict / Compounds / SCHEMBL19713085

SCHEMBL19713085

SCHEMBL19713085

CC(=O)Nc1ccc(/C=C/c2ccc(NC(=S)NC(C)C)cc2S(=O)(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 0.62
▸ RAB9A P51151 1/20 0.50
▸ APEX1 P27695 1/20 0.47
▸ RAD51 Q06609 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ PKM P14618 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19713084 1.00 ENPP2 (0.62) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL14358601 0.94 ENPP2 (0.69) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL14358597 0.94 ENPP2 (0.69) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL17822263 0.89 ENPP2 (0.62) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL17822264 0.89 ENPP2 (0.62) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL19726895 0.89 ENPP2 (0.49) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL14361680 0.89 ENPP2 (0.58) ENPP2RAB9ARAD51KDM4EMAPT
SCHEMBL14361673 0.89 ENPP2 (0.58) ENPP2RAB9ARAD51KDM4EMAPT
SCHEMBL17830467 0.88 RAB9A (0.47) ENPP2RAB9AAPEX1RAD51KDM4E
SCHEMBL19733540 0.87 ENPP2 (0.62) ENPP2RAB9AAPEX1RAD51MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927075-B2 Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease THE JACKSON LABORATORY (US) 2021-02-23 — — US disclosed
US-20170362172-A1 COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE THE JACKSON LABORATORY (US) 2017-12-21 — — US disclosed
US-20170362172-A1 COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE THE JACKSON LABORATORY (US) 2017-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362172-A1 COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE OGG1, MGMT, TDP1 ENPP2 225/4885RAB9A 2826/4885APEX1 38/4885
US-10927075-B2 Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease OGG1, MGMT, TDP1 ENPP2 225/4885RAB9A 2826/4885APEX1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.